Stifel Nicolaus Says That Pacira Pharmaceuticals (NASDAQ:PCRX) Has $41 Stock Target

September 15, 2018 - By Harriett Tippett

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Logo

Investors sentiment is 0.93 in Q2 2018. Its the same as in 2018Q1. It has no change, as 26 investors sold Pacira Pharmaceuticals, Inc. shares while 46 reduced holdings. only 20 funds opened positions while 47 raised stakes. 40.41 million shares or 3.30% less from 41.78 million shares in 2018Q1 were reported.

Penn Capital Management Com holds 0.82% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 341,580 shares. Oak Ridge Ltd Liability Co owns 219,220 shares for 0.4% of their portfolio. Elk Creek Partners Limited Liability Company holds 2.41% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 1.37M shares. Vanguard Gru Incorporated Inc invested in 3.40M shares or 0% of the stock. Consonance Cap Mgmt Lp reported 7.76% stake. 521,379 were accumulated by Schroder Invest Mngmt Gp. 15,000 are held by Assets Invest Mngmt Ltd Liability Company. Td Asset Mgmt reported 27,200 shares. Malaga Cove Lc owns 22,882 shares or 0.37% of their US portfolio. Sei Invests holds 2,993 shares. 30,037 are owned by Manufacturers Life Ins Com The. Dekabank Deutsche Girozentrale invested in 19,155 shares. Price T Rowe Md invested in 0.01% or 1.66M shares. Avenir holds 0.07% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 20,080 shares. Fincl Architects Inc reported 1,722 shares.

Since May 15, 2018, it had 1 insider buy, and 10 selling transactions for $1.97 million activity. Williams Kristen Marie sold $67,361 worth of stock or 2,040 shares. Shares for $23,378 were sold by Reinhart Charles A. III on Monday, June 4. HASTINGS PAUL J sold $26,137 worth of stock or 771 shares. $44,611 worth of stock was bought by Kronenfeld Mark A. on Tuesday, August 28. Scranton Richard sold $45,138 worth of stock. Shares for $74,148 were sold by Riker Lauren Bullaro on Wednesday, August 22.

Why Has Stifel Nicolaus Given Pacira Pharmaceuticals (NASDAQ:PCRX) a $41 Price Target

Analysts at Stifel Nicolaus has begun coverage on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research report revealed to clients on 14 September. The financial company set “Sell” rating on the $1.91B market cap company.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 13 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 7 have Buy rating, 1 Sell and 5 Hold. Therefore 54% are positive. Pacira Pharmaceuticals has $85 highest and $2700 lowest target. $45.45’s average target is -2.36% below currents $46.55 stock price. Pacira Pharmaceuticals had 20 analyst reports since March 20, 2018 according to SRatingsIntel. The firm has “Market Perform” rating given on Monday, April 9 by BMO Capital Markets. The company was maintained on Tuesday, May 29 by Mizuho. The firm has “Buy” rating by Piper Jaffray given on Monday, April 9. The firm has “Hold” rating by Canaccord Genuity given on Monday, April 9. H.C. Wainwright maintained the shares of PCRX in report on Thursday, May 3 with “Buy” rating. The firm has “Buy” rating given on Thursday, April 5 by Wedbush. The rating was maintained by Wedbush on Monday, April 30 with “Buy”. On Monday, August 6 the stock rating was downgraded by Bank of America to “Neutral”. The firm earned “Neutral” rating on Tuesday, April 10 by JP Morgan. The rating was maintained by H.C. Wainwright on Monday, April 9 with “Buy”.

The stock decreased 1.69% or $0.8 during the last trading session, reaching $46.55. About 455,970 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 23.87% since September 15, 2017 and is uptrending. It has outperformed by 8.25% the S&P500.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on November, 14. They expect $-0.05 EPS, up 54.55 % or $0.06 from last year’s $-0.11 per share. After $0.07 actual EPS reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -171.43 % negative EPS growth.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.91 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

More recent Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news were published by: Seekingalpha.com which released: “Pacira Pharmaceuticals Is A Solid Buy For 2018” on August 21, 2018. Also Nasdaq.com published the news titled: “Consolidated Research: 2018 Summary Expectations for SpartanNash, Encana, Hilltop, Pacira Pharmaceuticals …” on August 23, 2018. Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For September 14, 2018” with publication date: September 14, 2018 was also an interesting one.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.